Introduction {#Sec15}
============

Based on their diagnostic descriptions, attention-deficit/hyperactivity disorder (ADHD) and Autism Spectrum Disorder (ASD) have little in common. ADHD is characterized by severe inattention, hyperactivity, and impulsivity, whereas ASD is characterized by impaired communication and social interaction skills, as well as repetitive and restricted behavior and interests \[[@CR3]\]. However, in clinical practice it is commonly observed that a child with ADHD shows symptoms of ASD and vice versa. Moreover, ADHD and ASD appear to co-occur in families, with one child for instance having ADHD and the other child having ASD or a combination of both disorders. Despite these clinical observations, the diagnostic guidelines in the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) \[[@CR3]\] prevent making a comorbid diagnosis, based on the rationale that ADHD-like symptoms in patients with ASD are primarily attributable to the ASD diagnosis. This argument is widely disputed, and it is now commonly believed that both disorders can co-occur.

Several studies have made an estimation of the co-occurrence rates of ADHD and ASD, by examining the prevalence of ASD in ADHD samples and vice versa. Estimations vary substantially; based on the lowest and highest reported prevalence rates, 20--50% of children with ADHD meet criteria for ASD and 30-80% of ASD children meet criteria for ADHD \[[@CR20], [@CR32], [@CR43], [@CR47], [@CR51], [@CR81], [@CR86], [@CR88], [@CR100]\]. Much less is known about co-occurrence rates in adults. Two studies indicate that 40--50% of patients with autistic disorder or atypical autism, 28--36% of patients with Asperger syndrome and around 52% of patients with PDD-NOS, fulfill the criteria for ADHD (including ADHD in remission) \[[@CR4], [@CR46]\]. The interpretation of comorbidity rates from clinical samples, however, is limited due to possible referral bias. A further complicating factor in all of these studies, is the entanglement of symptom descriptions of both disorders. That is, inattention (a core symptom of ADHD) can easily be mistaken for social inattention (a core symptom of ASD), resulting in inflated co-occurrence rates of both disorders. Ideally, prevalence rates of ADHD in ASD are calculated both in a loose manner and a stringent manner, in which the latter refers to correcting for the population prevalence of ADHD when calculating prevalence rates of ADHD in an ASD sample and vice versa. Or, even better, a factor analysis on a pool of ADHD and ASD items should be performed, excluding the items that show too much cross-correlation, in order to extract more pure constructs of ADHD and ASD. Such a stringent approach to study the co-occurrence of ADHD and ASD, however, has yet to be performed. Nevertheless, despite the shortcomings of the studies reporting on co-occurrence rates of ADHD and ASD, it is undeniable that both disorders can co-occur in the same patient.

However, due to the *DSM*-*IV* diagnostic restrictions, little is known about the nature of the co-occurrence of ADHD and ASD. The co-occurrence of two disorders may be caused by a variety of reasons. First, as mentioned above, it may be related to overlapping diagnostic criteria, resulting in inflated co-occurrence rates. As far as the authors know, no studies exist that have performed a factor analysis on ADHD and ASD *DSM*-*IV* derived items to examine the extent of overlapping diagnostic criteria. Even though it is of vital concern to examine the interrelatedness of both construct descriptions, we do not believe the co-occurrence of ADHD and ASD can be completely explained by overlapping diagnostic criteria. Second, co-occurrence of ADHD and ASD may be caused by one disorder leading to the other. In this scenario, treatment of one disorder might improve symptoms of the other disorder as well. This appears not to be the case: Psychostimulants and noradrenergic reuptake inhibitors appear effective in the treatment of ADHD symptoms in patients with a combined diagnosis of ADHD + ASD, but do not have a substantial effect on the ASD symptoms \[[@CR2], [@CR41], [@CR70], [@CR83], [@CR95]\]. Also the age of onset and developmental sequence of ASD and ADHD do not support a likely model of one disorder leading to the other. For ASD has by definition an earlier onset than ADHD, and would then be causing ADHD. However, in most if not all ASD plus ADHD cases the first clinical presentation includes the simultaneous expression of ASD and ADHD symptoms. Another theoretical possibility is that one of the disorders produces a phenocopy of the other. A phenocopy is an individual whose phenotype, under a particular environmental condition, is identical to the one of another individual whose phenotype is determined by the genotype. In other words, the phenocopy environmental condition mimics the phenotype produced by a gene. An example of a phenocopy in the context of this paper would be a child with a strong genetic predisposition for ADHD but growing up in a rigid, bizar, and unempathic family. This could lead to the expression of the ADHD phenotype, on the basis of the genotype, in addition to the expression of an ASD phenotype, on the basis of the specific environmental condition. This does not seem to be a likely model, however. Two final explanations for the co-occurrence of ADHD and ASD may be that they are separable and independent disorders occurring together---for example by their association with a third independent factor---or alternatively, they share a common underlying etiology \[[@CR6], [@CR10], [@CR15], [@CR19], [@CR36]\]. We believe that the latter is true and the most likely model, and that both disorders partly shared a common genetic basis. This will be the main topic of the current review.

Both ADHD and ASD are disorders with a strong heritable component. In ADHD, approximately 76% of the phenotypic variance is explained by heritable factors \[[@CR29]\]; in ASD, heritability has been estimated as \>90% for the narrow sense phenotype of classic autism \[[@CR33]\], but may be lower for the broad sense phenotype (although the broad sense phenotype is more prevalent amongst first- and second-degree relatives of ASD probands \[[@CR69]\]). For both disorders, oligogenic and multifactorial modes of inheritance have been proposed, but relatively little progress has yet been made in identifying the genes involved \[[@CR31], [@CR33]\]. This may be (partly) due to clinical and genetic heterogeneity \[[@CR55]\] as well as to other factors \[[@CR18]\]. How then should we proceed in our search for common genetic risk factors for ADHD and ASD? We will try to answer this question by systematically reviewing the literature for studies that have examined ADHD and ASD in a family-based design or in a twin design. The former will provide insight into the familiality (caused by both heritable factors as well as shared environmental factors) of ADHD + ASD. The latter more directly examines the extent of common genetic factors underlying ADHD + ASD, but has the disadvantage that findings are most often based on community samples instead of clinical samples. The disadvantage of community twin samples is that they have a very low rate of clinical disorders such as ASD. Community twin samples are very useful for the study of subclinical traits across the continuum but much less for clinical disorders as ASD. In addition, we provide an overview of possible overlapping candidate genes and genome-wide association findings for both disorders. A summary is provided with candidate endophenotypic measures (heritable, vulnerability traits) that may be useful for unraveling the shared etiological underpinnings of ADHD and ASD. Finally, we propose several steps for future molecular genetic studies. By providing a comprehensive overview of the currently available findings with respect to shared genetic underpinnings of ADHD and ASD, the current review aims to make an important contribution to the research field and facilitate future genetic studies for ADHD + ASD.

Familial aggregation {#Sec1}
====================

Only two related studies originating from the IMAGE cohort (International Multicenter ADHD Genetic study) \[[@CR7]\] have examined the rates/severity of ASD in probands with ADHD and their siblings \[[@CR61], [@CR64]\]. Importantly, in both studies, probands and siblings with full autistic disorder were excluded from participation. As far as we know, no studies exist reporting on ADHD in family members of ASD probands. In the Mulligan et al. study \[[@CR61]\], autism symptoms were measured using the Social Communication Questionnaire (SCQ) and compared in 821 ADHD probands, 1,050 siblings and 149 controls. As expected, probands (males and females) had higher SCQ scores than siblings and controls. In turn, affected and unaffected male siblings, but not female siblings, had higher SCQ scores than controls. The phenotypic correlation between ADHD and ASD was also slightly higher for males (0.63) than females (0.49). The sibling cross-correlation, indicative of shared familial influences on ADHD and ASD was 0.18 for males, of which 56% can be attributed to shared genetic influences on ADHD and ASD. This percentage has been calculated by a modified method of the deFries-Fulker analysis. In this analysis, a comparison is made of the mean symptom scores of the proband and the sibling with the mean population scores. See Mulligan et al. \[[@CR61]\] for details. These findings suggest that, at least in males, ASD symptoms are familial within ADHD families which likely represent genetic rather than shared environmental factors. While results did not support this hypothesis in females, it must be noted that due to the large predominance of male patients in the sample (88%), cross-correlation could not be robustly estimated and firm conclusions regarding the shared familiality of ADHD and ASD symptoms in females cannot be drawn.

In the Nijmeijer et al. study \[[@CR64]\], a similar approach was taken on the Dutch subsample of the IMAGE dataset. ASD symptoms were measured using the Children's Social Behavior Questionnaire (CSBQ) in 256 sibling pairs and 147 controls. Some important differences exist between the CSBQ used in the Nijmeijer et al. study and the SCQ used in the Mulligan et al. study. The 49-item CSBQ is an instrument able to measure less severe variants of ASD symptomatology and ASD related problems (such as problems in executive functioning and disruptive behavior), whereas the SCQ is designed to measure the more severe ASD characteristics. Furthermore, the CSBQ uses a 3-point Likert-scale, in contrast to the 'yes' and 'no' response options used in the SCQ. Similarly, the study of Mulligan et al. indicated that both probands and siblings had higher ASD scores than controls, ADHD and ASD correlated phenotypically (0.40) and sibling correlations for ASD were significant. Contrary to the results of the Mulligan study was the finding that the sibling correlations for ASD were higher in female probands (0.44) than male probands (0.23), suggesting ASD to be more highly familial in females with ADHD compared to males with ADHD. In addition, sibling correlations for ASD were generally higher in older than younger children, possibly indicating an increased genetic influence on ASD within ADHD families over time. Last, sibling cross-correlations between ADHD and ASD were non-significant, suggesting that independent familial factors give rise to ADHD and ASD. This latter finding contrasts somewhat with the significant albeit small (*r* = 0.18) sibling cross-correlations for ADHD and ASD reported by Mulligan et al. yet may be explained by the substantially smaller sample size and use of a qualitatively different questionnaire in the Nijmeijer et al. study. However, it is safe to say that ASD symptoms are familial within ADHD families, as indicated by elevated ASD symptom levels in affected and non-affected siblings of ADHD probands and significant sibling correlations. Whether ADHD and ASD symptoms arise from shared familial (and genetic) origins within clinically ADHD affected children, and whether this is influenced by age and gender, remains to be investigated.

Twin studies {#Sec2}
============

Constantino et al. \[[@CR23]\] were the first to report shared additive genetic influences on symptoms of ASD (measured with the Social Reciprocity Scale) and attention problems (measured with the Child Behavior Checklist) in 219 pairs of male twins aged 7--15 years. Two recent twin studies examined more directly the genetic correlations between ADHD and ASD symptoms \[[@CR75], [@CR79]\]. One study examined parent and teacher reported symptoms of ADHD (using the Conners') and ASD (using the Childhood Asperger Syndrome Test) in a large (*N* = 6,771) sample of 8 year old twins \[[@CR79]\]. Phenotypic correlations between ADHD and ASD were 0.54 for parent and 0.51 for teacher data. Genetic correlations between ASD and ADHD symptoms were all \>0.50, suggesting a moderate degree of overlap between ASD and ADHD, both throughout the general population and at the quantitative extreme. A model incorporating additive genetic influences and unique environmental influences fitted the data best. Findings were robust for influences of rater, sex, IQ, and comorbid conduct problems.

Quite similar results were reported in a study using self reported measures of ADHD (12 *DSM*-*IV* items) and ASD (Social Responsiveness Scale) in young adult twins (*N* = 674) \[[@CR75]\]. A bivariate model indicated that the genetic correlation between ADHD and ASD was 0.72, suggesting that a substantial proportion of the genetic influences on self-reported ADHD and ASD symptoms may be shared between the two disorders. Again, models with additive genetic effects and unique environmental effects fitted the data best, with no evidence for sex differences.

Molecular genetic studies {#Sec3}
=========================

Candidate genes {#Sec4}
---------------

Abnormal functioning of catecholaminergic and serotonergic neurotransmission has been reported in both ADHD and ASD \[[@CR14], [@CR66], [@CR72]\]. The main focus in ADHD literature has been on dopamine related genes, given that alterations in dopamine neurotransmission is a core feature of ADHD \[[@CR94]\]. The main focus in ASD literature has been on serotonin related genes, given that abnormalities in serotonin neurotransmission are robustly reported in ASD \[[@CR48]\]. Accordingly, genes related to these pathways have been the prime candidates for molecular investigation in both disorders \[[@CR5], [@CR87]; see also elsewhere in this issue\].

Dopamine {#Sec5}
--------

The dopamine transporter gene (*DAT1*), coding for a sodium-dependent dopamine transporter that mediates reuptake of dopamine at the synapse, is associated with ADHD (see for meta-analysis \[[@CR37]\]). The most frequently studied polymorphism is a 40 base pair (bp) variable number of tandem repeat (VNTR) in the 3′-untranslated region. The 9- and 10-repeat alleles are the two most common variants in Caucasians. The 10-repeat is associated with an increased activity of the transporter, resulting in less dopamine in the synaptic cleft. A recent study investigated the association between *DAT1* and ADHD symptomatology in 67 children with ASD \[[@CR34]\]. In contrast to expectations, the 10/10 homozygous ASD children were rated by mothers as being less inattentive and hyperactive-impulsive than the 9-repeat carriers. However, given that findings of the 9- versus 10-repeat allele are also mixed in ADHD literature (Franke et al. submitted), with the latter sometimes being the risk variant, other times the protective variant \[[@CR37]\], further studies are needed to clarify the role that *DAT1* may play in relation to ADHD + ASD symptomatology.

Another extensively studied candidate gene for ADHD is the dopamine D4 receptor gene (*DRD4*). A specific variant of the *DRD4* gene associated with ADHD, as indicated by meta-analyses \[[@CR37], [@CR52]\], is the functional 48 bp VNTR in exon 3. The 7-repeat allele of this VNTR, identified as the risk allele for ADHD, produces fewer or less efficient D4 receptors resulting in less responsiveness to dopamine stimulation. However, when studied in relation to ASD, no association was found between this 7-repeat and autism in 136 autism probands recruited from the same geographic regions as a previous ADHD study conducted by the same authors \[[@CR40]\], suggesting *DRD4* may not be related to ASD.

The dopamine D3 receptor (DRD3) and the DRD4 have been classified as D2-like receptors based on their sequence homologies and similarity of pharmacological and biochemical properties \[[@CR76]\]. A possible association between ADHD and *DRD3* has been reported \[[@CR41], [@CR76]\], although a recent meta-analysis does not indicate *DRD3* to be significantly associated with ADHD \[[@CR37]\]. Recently, 132 candidate genes were tested for their association with ADHD and ASD in a two stage approach \[[@CR50]\]. First, single nucleotide polymorphisms (SNPs) were tested in 144 ASD patients, 110 ADHD patients, and 404 controls. SNPs reaching a significant threshold for association (*p* \< 0.01) were tested in a second independent sample of 128 ASD patients, 150 ADHD patients, and two samples of controls (*N* = 124 and 149). Results indicated that in the first and second ASD samples and in a joint statistical analysis, a significant association with SNP rs167771 located in the *DRD3* gene was found. The *DRD3* gene appeared to be related to stereotyped behavior, liability to side effects of antipsychotic medication, and movement disorders and may therefore have important clinical implications for ASD. Disappointingly, no shared association was found between ADHD and ASD. However, these results should be seen in light of virtually no significant SNP findings for both disorders. As the authors noted themselves, they used a strict (possibly overly conservative) Bonferroni correction, making it possible that they missed out on loci that were associated with ADHD and/or ASD.

Serotonin {#Sec6}
---------

ASD is related to serotonergic genes \[[@CR87]\]. The human serotonin transporter is encoded by the *SLC6A4*, *SERT*, *5*-*HTT* genes. The transcriptional activity of this gene is modulated by a repetitive element of differing length in the promoter. A short version leads to a limited transcription and a reduced amount of the transporter. Studies on this polymorphism in relation to ADHD and ASD have been reviewed \[[@CR87]\]. The authors concluded that although there is some evidence supporting the association of the polymorphism with both ADHD and ASD, a uniform picture does not emerge and overlap in findings may be best described by dimensional classification of the two disorders. The advantage of the dimensional approach is that one takes full account of all information available. For example, individuals with moderately high but just subthreshold scores are lumped together with subjects with low scores in a categorical approach. In a dimensional approach, the quantitative difference between subthreshold and low scores is taken into account. The authors suggest that studies examining this polymorphism simultaneously in children with ADHD, ASD, and ADHD + ASD may be needed.

Other {#Sec7}
-----

Breakdown of the catecholamines dopamine, adrenaline, and noradrenaline is mediated by the enzyme Catechol-O-methyltransferase (COMT). Multiple studies have investigated the association between ADHD and a functional SNP, Val158Met (rs4680), associated with decreased enzyme activity (Met-allele) and leading to increased intra-synaptic amount of dopamine in the mesocortical dopamine pathway. Mixed results have been found (see for review elsewhere in this issue). A recent study reported that this functional SNP was also related to social phobia in subjects with ASD \[[@CR35]\]. However, no relationship was found with ADHD measures within the sample, yet given the small sample size (*N* = 67) no firm conclusions can be drawn on the validity of the *COMT* gene as a pleiotropic ADHD/ASD gene.

The X-chromosomal gene Monoamine Oxidase A (*MAOA*) gene codes for a mitochondrial enzyme involved in the pre-synaptic degradation of the monoamines serotonin, norepinephrine, and dopamine \[[@CR24]\]. The gene is a candidate for ADHD because it influences those monoaminergic systems that are also etiologically related to ADHD \[[@CR25]\] and MAOA activity can be inhibited by methylphenidate, which also reduces ADHD symptoms. Several studies have indeed found various polymorphisms in *MAOA* (like a 30 bp repeat in the promoter region, a GA repeat in intron 2, and a G/T in exon 8) to be associated with ADHD, with small odds ratio's around 1.31 and 1.94 \[[@CR17], [@CR25], [@CR26], [@CR40], [@CR55]; see also elsewhere in this issue). A recent study employing a small sample size (*N* = 43) of boys with ASD reported an association between the 30 bp VNTR in the promoter region of the *MAOA* gene and severity of ADHD in these boys \[[@CR80]\]. As the authors indicate, these results suggest that behavioral disturbances in children with and without ASD may share similar pathogenic mechanisms.

Rare mutations {#Sec8}
--------------

In some cases, a combined diagnosis of ASD and ADHD may be attributable to a premutation in the 5′ untranslated region of the *FMR1* gene on the X-chromosome. A full mutation in this region (\>200 repeats of a CGG trinucleotide) results in Fragile X syndrome, the most common heritable form of mental retardation \[[@CR30]\]. Most individuals with fewer repeats (a premutation: 55--200 repeats) suffer from mild variants of cognitive and behavioral problems seen in individuals with the full mutation. The prevalence of the premutation in the general population (1:813 males and 1:259 females) is much higher than the prevalence of the full mutation alleles \[[@CR30]\], thereby making this premutation more relevant for clinical healthcare. Farzin et al. \[[@CR30]\] showed that in a relatively small sample (*N* = 43) of boys (27 premutation carriers and 16 non-carrier siblings), the premutation was significantly associated with both clinical diagnosis of ASD as well as ADHD symptoms. Thus, in some cases, a combined diagnosis may be linked to premutations in the *FMR1* gene on the X-chromosome.

In other rare cases, segmental duplications at breakpoints (BP4-BP5) of chromosome 15q13.2-q13.3 may be the underlying cause of ADHD + ASD \[[@CR59]\]. The proximal portion of chromosome 15q is a well-known region of genomic instability that contains many segmental duplications. Deletions at 15q11-q13 on the known breakpoint BP1, BP2, and BP3 can result in Prader-Willi syndrome and Angelman syndrome \[[@CR59]\]. A recent study reported on the clinical features of five patients with a BP4-BP5 deletion, three with a BP4-BP5 duplication, and two with an overlapping but smaller duplication extracted from a DNA database of 1,445 unrelated patients submitted consecutively for clinical array comparative genomic hybridisation (CGH) testing at Children's Hospital, Boston and of 1,441 individuals with autism from 751 families in the Autism Genetic Resource Exchange (AGRE) repository. Results indicated that the phenotype of microdeletions or duplications at breakpoints BP4 and BP5 were related to ASD, ADHD, minor dysmorphic features, expressive language deficits and cognitive impairment \[[@CR59]\].

A deletion of 22q11 (containing the *COMT* gene) may also be underlying ADHD + ASD in some rare cases. In 100 cases with this deletion, the known cause of velocardiofacial (VCF) or DiGeorge syndrome, 44% were diagnosed with at least one of both disorders \[[@CR65]\]. Nine percent of cases had a combined diagnosis. In addition, mental retardation was also common.

The rare XXYY syndrome (prevalence 1:18,000--40,000) may account for a few ADHD + ASD cases as well. In 95 males with this syndrome, over 72% had ADHD and over 28% had ASD \[[@CR92]\]. However, given that this syndrome is accompanied by characteristic physical and facial abnormalities (such as tall stature, hypogonadism, dental problems, seizures, infertility) and almost half of the patients show clear white matter abnormalities and enlarged ventricles \[[@CR92]\], this syndrome is unlikely to account for many ADHD + ASD cases without clear medical cause. In fact, this conclusion holds for most of the aforementioned rare mutations.

Recently, a plethora of new information on rare mutations (copy number variations, CNVs) and their possible role in ASD has been generated by the genome-wide copy number analyses \[[@CR17], [@CR22], [@CR38], [@CR57], [@CR85], [@CR102]; see also the Autism Chromosome Rearrangement Database (<http://projects.tcag.ca/autism/>)\]. These studies suggest that a considerable number of ASD cases may be explained by rare genetic variants of intermediate to large effect size. One recent study also reports on genome-wide CNV analysis in ADHD \[[@CR28]\]. These findings also help to clarify the joint etiology of ADHD and ASD, which remains to be investigated. Interestingly, though, in the study by Elia et al. \[[@CR28]\] CNVs segregating with ADHD were found to be enriched for ASD candidate genes, while in several of the ASD CNV studies, family members of the ASD patients also carrying the CNV had diagnoses of ADHD \[[@CR57], [@CR98]\].

Possible overlapping linkage findings {#Sec9}
-------------------------------------

Linkage studies have been performed to identify new chromosomal loci harboring risk genes for ADHD and ASD. With the exception of one study, only an indirect comparison of candidate linkage loci for ADHD and ASD can be made, since all loci are based on studies including patients with either ADHD or ASD. In the latter case, probably ADHD + ASD cases were included, but this was not systematically registered or measured. The linkage study by Bakker et al. \[[@CR9]\] analyzed both a narrow phenotype, in which only sib pairs with ADHD were included (*N* = 117), and a broad phenotype, containing additional sib pairs (*N* = 47), in which one child had an autistic-spectrum disorder but also met the full ADHD criteria. For this broad phenotype, suggestive linkage was observed on chromosome 15q15. An overview of the ADHD- or ASD-specific literature provides limited supporting evidence for overlap. When applying a threshold of 2.2 for the multipoint logarithm of odds score (MLS), indicative of suggestive linkage, the ASD regions for suggestive linkage (2q31, 3q26, 7q22, 7q36, 11p12-13, and 17q11) and those for ADHD (5q13, 5q33, 6q12, 6q22-23, 7p13, 7q21, 9q22, 9q33, 11q22, 14q12, 15q15.1, 16p13, 16q23, 16q24, and 17p11) show no overlap between ASD and ADHD \[[@CR47]\]. If even looser criteria are applied, linkage peaks for ADHD at 2q24, 9q33, 5p13, 15q, 16p1, 16p13, and 17p11 are in the proximity of peaks previously detected in genome scans for autism \[[@CR44], [@CR87]\]. If confirmed, such regions may harbor pleiotropic genes for ADHD and ASD. The 16p13 peak was observed by Smalley et al. \[[@CR89]\] in an ADHD affected-sib-pair analysis in 203 families. They found a significant linkage signal (maximum LOD 4.2) on a 12-cM region on chromosome 16p13, a region already highlighted in three genome scans for ASD. As yet, this linkage signal and those on 5p13 \[[@CR8], [@CR49], [@CR53], [@CR67], [@CR99]\] and 9q33 \[[@CR8], [@CR77], [@CR84]\] may appear to be the most fruitful loci to search for pleiotropic genes, since both of these loci are supported by at least two independent studies of autism (although not necessarily genome wide significant), and at least one study of ADHD. However, linkage studies of ADHD + ASD samples are warranted before firm conclusions can be drawn.

Genome-wide association studies (GWAS) {#Sec10}
--------------------------------------

Molecular genetic studies are increasingly using genome-wide association study (GWAS) designs. This new analytic approach combines the power to detect genetic variants of small effect size with the possibility to perform hypothesis-free analyses of the entire genome \[[@CR31]\]. In GWAS, 100,000 to over 1,000,000 single nucleotide polymorphisms (SNPs) are genotyped across the genome and tested for their association with the disorder. Given that GWA studies are still in their very early beginning, it may be somewhat premature to look for overlapping findings for ADHD and ASD. Nevertheless, Franke et al. \[[@CR31]\] recently reviewed the GWAS literature for SNPs associated with ADHD and several of the top-findings from the reviewed studies turned out to be located near to linkage findings in ASD. A summary of these findings for 16 SNPs possibly involved in ASD is given in Table [1](#Tab1){ref-type="table"}. Similarly, we reviewed the literature for SNPs from SNP-based GWAS in ASD \[[@CR54], [@CR96]; genome-wide ASD CNV studies were already mentioned above\]. We report in Table [2](#Tab2){ref-type="table"} ASD GWAS findings that may also be involved in ADHD. Twenty-five SNPs related to ASD, may also be of interest to ADHD. As already indicated above, (rare) CNVs might also indicate genes pleiotropic for ASD and ADHD.Table 1Overview of single nucleotide polymorphisms (SNPs) among the top-findings of GWAS in ADHD possibly also involved in ASD (based on Franke et al. \[[@CR31]\])SNPChrPosition (bp)PositionGene function^a^Previous findings for ASD^a^rs2720002116372265Within 50 kb downstream of *DPP10*Encodes dipeptyl peptidase 10, which does not possess dipeptidyl peptidase activity, but binds to specific voltage-gated potassium channels and alters their expression and biophysical properties. The expression of the gene is highest in the brain.The gene contains CNVs potentially linked to autism \[[@CR57]\].rs100492463187169435Intron of *AK309325*Hypothetical gene of unknown function.SNP lies in a linkage region for autism \[[@CR57]\].rs6791644360746148Intron of *FHIT*Encodes a diadenosine 5′,5′′′-P1,P3-triphosphate hydrolase involved in purine metabolism. FHIT has a major role in regulating beta-catenin-mediated gene transcription. Expression in many tissues including the brain.Gene is affected by CNVs in autism \[[@CR57], [@CR85]\].rs109832389q33.1118373504Intron of *ASTN2*Encodes astrotactin 2, a membrane protein expressed in multiple tissues including the brain. It is critically involved in neuron-glia binding during the developmental periods of glial-guided cell migration and assembly into neuronal layers in the developing brain. A homologue of the gene, *ASTN*, is involved in neuronal migration.The gene was found disrupted by rare CNVs in patients with autism \[[@CR57]\].rs176417891046959Coding exon of *DMRT2*Encodes doublesex and mab-3 related transcription factor 2, a potential regulator of sex differentiation. Expressed in multiple tissues, including the brain.Site is known for CNVs. Falls into/close to a suggestive linkage region for autism \[[@CR1], [@CR8]\].rs389321511p15.117721406Intron of *KCNC1*Encodes potassium voltage-gated channel Shaw-related subfamily member 1, a protein belonging to the delayed rectifier class of channel proteins and an integral membrane protein that mediates the voltage-dependent potassium ion permeability of excitable membranes.The SNP is close to/within regions of (suggestive) linkage to autism from a meta-analysis \[[@CR93]\] and primary studies \[[@CR8], [@CR27]\].rs8744261119526139Intron of *NAV2*Encodes neuron navigator 2, an retinoic acid-responsive gene that seems to play a role in neuronal development. It is highly expressed in the fetal and adult brain.The SNP is close to/within regions of (suggestive) linkage to autism from a meta-analysis \[[@CR93]\] and primary studies \[[@CR8], [@CR27]\].rs799521513q31.393206507Intron of *GPC6*Encodes glypican 6. The glypicans comprise a family of glycosylphosphatidylinositol-anchored heparin sulfate proteoglycans. The glypicans have been implicated in the control of cell growth and division. Glypican 6 is a putative cell surface coreceptor for growth factors, extracellular matrix proteins, proteases and anti-proteases. Expressed in multiple tissues including the brain.CNVs in the gene have been noted in a study on autism \[[@CR57]\].rs23609971475882244Within 25 kb upstream of *ESRRB*Encodes estrogen-related receptor beta, a protein with similarity to the estrogen receptor, expressed in brain and other tissues.CNVs in the gene have been noted in a study on autism \[[@CR57]\].rs716433515q2366502086*ITGA11*Encodes integrin alpha 11. Integrins are heterodimeric integral membrame proteins composed of an alpha chain and a beta chain. The gene is expressed in multiple tissues including the brain.The SNP lies close to linkage regions for autism \[[@CR8]\].rs267774415q26.189251445Intron of *MAN2A2*Encodes mannosidase, alpha, class 2a, member 2, expressed in the brain and many other tissues. The protein is involved in N-glycan synthesis.SNP lies close to linkage regions for autism \[[@CR8]\].rs14712251527675688Within 30 kb downstream of *KIAA0574*Encodes protein of unknown function expressed in the brain and other tissues.The site is found in CNV regions in 3 studies of autism \[[@CR22], [@CR57], [@CR85]\].rs74950521590353033Intron of *SLCO3A1*Encodes solute carrier organic anion transporter family, member 3A1, which might be involved in the regulation of extracellular vasopressin concentration in the human brain and thus might influence the neuromodulation of neurotransmission by cerebral neuropeptides such as vasopressin.In/near suggestive linkage regions for autism \[[@CR8]\].rs71872231681015234Intergenic, within 203 kb upstream from *CDH13*Encodes cadherin 13, a member of the cadherin superfamily. The encoded protein is a calcium-dependent cell--cell adhesion glycoprotein. This particular cadherin is a putative mediator of cell--cell interaction in the heart and may act as a negative regulator of neural cell growth.The gene shows CNVs potentially related to autism \[[@CR22]\].rs65651131681665146Intron of *CDH13*See aboveSee abovers48106852045834120Intron of *SULF2*Encodes heparin sulfatase 2. Heparan sulfate proteoglycans (HSPGs) act as coreceptors for numerous heparin-binding growth factors and cytokines and are involved in cell signaling. *SULF2* can change properties of the coreceptors by removing sulfate moieties. The gene is essential for mammalian development and survival, it shows ubiquitous expression.The SNP lies close to a linkage region for autism \[[@CR1]\].^a^Where not indicated otherwise, the information is derived from the UCSC Browser, NCBI's OMIM, Gene and Unigene databases, and the Sullivan Lab Evidence Project website (location of SNP expanded by ±5 Mb for genome-wide linkage scans, ±5 kb for GWAS, microarray and CNV studies, and ± 50 kb for signposts)*ADHD* attention-deficit/hyperactivity disorder, *ASD* autism spectrum disorders, *CNV* copy number variation, *SNP* single nucleotide polymorphismTable 2Overview of single nucleotide polymorphisms (SNPs) among the published top-findings of GWAS in ASD which may also be involved in ADHDSNP/CNVChrPosition (bp)PositionGene function^a^Previous findings for ADHD^a^Wang et al. \[[@CR96]\] 6 SNPs5p14.125934678--26008578Between *CDH9* and *CDH10*The genes encode type II classical cadherins from the cadherin superfamily, integral membrane proteins that mediate calcium-dependent cell--cell adhesion. Both are expressed in brain.The SNPs lie close to a linkage region for ADHD \[[@CR44]\]. rs9395885, rs93496886p12.153853436--53870051Within intron of *LRRC1*Ecodes leucine-rich repeat-containing protein 1, a membrane protein of unknown function found in epithelia (and brain).The SNPs are within a region of suggestive linkage to ADHD from a meta-analysis \[[@CR101]\]. rs93849526p22.1116066757IntergenicThe SNPs are within a region of suggestive linkage to ADHD from a meta-analysis \[[@CR101]\]. 8 SNPs13q33.3108823637--108881899Within 200 kb downstream of *MYO16*Encodes myosin heavy chain Myr 8, a gene highly expressed in brain. This cytoskeletal motor protein is involved in brain (especially cerebellum) development.The SNPs lie close to suggestive linkage result for ADHD \[[@CR9]\]. rs993253816p12.319116070Within intron of *SYT17*The product of this gene, synaptotagmin XVII (or B/K protein), is involved in vesicle transport and is highly expressed in brain, especially in the frontal and temporal lobes, the hippocampus, the hypothalamus, the amygdala, the substantia nigra, and the pituitary \[[@CR21]\]The SNP lies close to significant linkage result for ADHD \[[@CR67]\].Ma et al. \[[@CR54]\]^b^ 5 SNPs5p1425934777--25970827Between *CDH9* and *CDH10*The genes encode type II classical cadherins from the cadherin superfamily, integral membrane proteins that mediate calcium-dependent cell--cell adhesion. Both are expressed in brain. See also above, same findings reported by Wang et al. \[[@CR96]\].The SNPs lie close to a linkage region for ADHD \[[@CR44]\]. rs2528795773111430Within intron of *ELN*This gene encodes the elastin isoform a precursor. The mature protein that is one of the two components of elastic fibers. The encoded protein is rich in hydrophobic amino acids such as glycine and proline, which form mobile hydrophobic regions bounded by crosslinks between lysine residues. Deletions and mutations result in severe anomalies of the aorta and skin, but the gene also falls into the deletion found in Williams Beuren syndrome. The latter is a contiguous gene syndrome with neurobehavioral features and mental retardation not easily accounted for by the disruption of the elastin gene alone.The SNP lies within suggestive linkage region for ADHD from meta-analysis \[[@CR101]\]. rs1714152058229934Within intron of hypothetical genes *AX747739* and *AK309218*Hypothetical gene(s) of unknown function.Less than 10 kb from one of the top-findings of GWAS for ADHD \[[@CR63]\].*ADHD* attention-deficit/hyperactivity disorder, *ASD* autism spectrum disorders, *CNV* copy number variation, *SNP* single nucleotide polymorphism^a^Where not indicated otherwise, the information is derived from the UCSC Browser, NCBI's OMIM, Gene and Unigene databases, and the Sullivan Lab Evidence Project website (location of SNP expanded by ±5 Mb for genome-wide linkage scans, ±5 kb for GWAS, microarray and CNV studies, and ±50 kb for signposts)^b^Analysis was limited to SNPs showing *p*-values of 10^−4^ or smaller in the combined analysis of discovery and replication dataset

Summary of shared heritability findings for ADHD and ASD {#Sec11}
========================================================

Family based studies in clinical ADHD samples indicate that ASD symptoms are familial within ADHD families, and possibly related to similar familial origins as the ADHD symptoms. Twin studies suggest that 50-72% of the phenotypic variance may be attributable to shared additive genetic factors. It appears that findings are robust for influences of gender, albeit inconsistent results are reported concerning this issue in family based studies on the one hand (more familial in males in one study and more familial in females in another study) and twin studies on the other hand (no effect of gender). In addition, age may have an effect with shared heritability estimates possibly increasing with older age. A few candidate gene studies have examined the association with candidate genes for one disorder in relationship to the other disorder. *DAT1*, *DRD3*, *DRD4*, *COMT* and *MAOA* (ADHD candidate genes) have been examined for their association with ASD. Findings for *DRD4* were negative, for *DAT1* and *COMT* inconclusive, and for *DRD3* and *MAOA* at best cautiously positive. Serotonin related genes (ASD candidate genes) may be related to ADHD as well, yet no uniform picture emerges (reviewed elsewhere \[[@CR87]\]). However, these candidate gene studies are largely underpowered, prohibiting firm conclusions regarding these findings. In some cases, rare mutations (such as copy number variations (CNVs), premutations in the 5′ untranslated region of the *FMR1* gene on the X-chromosome, segmental duplications at breakpoints (BP4-BP5) of chromosome 15q13.2-q13.3, a deletion of 22q11 containing the *COMT* gene, and the rare XXYY syndrome) may account for some ADHD + ASD cases. However, given that these syndromes are mostly accompanied by characteristic physical abnormalities, they are unlikely to account for many ADHD + ASD cases without clear medical cause. With the exception of one study, only an indirect comparison of candidate linkage loci for ADHD and ASD can be made, since all loci are based on studies including patients with either ADHD or ASD. Limited evidence for overlap is found for overlapping suggestive linkage signals for ADHD and ASD. When applying looser criteria, 5p13, 9q33, and 16p13 appear to be the most fruitful loci to search for pleiotropic genes. With respect to GWAS findings, 16 SNPs related to ADHD may possibly involved in ASD and 25 SNPs related to ASD may also be of interest to ADHD. However, GWA studies are still in their very early beginning, so it may be somewhat premature to look for overlapping findings for ADHD and ASD.

Recommendations for future genetic studies of ADHD + ASD {#Sec12}
========================================================

GWAS have provided us with a tool to identify new genes for multifactorial disorders like ASD and ADHD. These studies require large samples to be investigated, with thousands of cases and equal numbers of controls to be analyzed. For this, international collaborations are being formed; one of the largest ones for psychiatric disorders being the Psychiatric GWAS Consortium \[[@CR74]\]. One of the three main objectives of the Psychiatric GWAS Consortium is "cross-disorder analyses, including analyses of combinations of disorders and of phenotypes observed in two or more disorders ... based on recommendations of an expert committee. Because data are insufficient to determine what common cross-disorder etiological factors might exist, alternative phenotypes should be explored. GWAS analyses have produced surprising cross-disorder associations, such as those found for cancers and inflammatory bowel diseases, which could also exist for psychiatric disorders given the many common symptoms" (p. 548 \[[@CR73]\]). No such cross-disorder analyses have been conducted for ADHD in combination with ASD. Therefore, we will propose several steps for future research that may facilitate the detection of pleiotropic etiological factors for ADHD and ASD.

A first step in future family genetic studies on the shared etiology of ADHD and ASD would be to assess ADHD and ASD in both parents and (multiple) off-spring. If parents and children are assessed using comparable phenotypic measures, a more direct examination can be made for inter-generational transmission of ADHD, ASD, and ADHD + ASD symptoms. It is of crucial importance to include not only categorical measures of ADHD and ASD into this design, but also to make use of quantitative phenotypic measures. The latter does more justice to the quantitative nature of both disorders; individuals with subthreshold symptoms are otherwise grouped together with individuals with no symptoms. Two types of families would be suitable for this approach: families in which the disorders are separately present in different family members, and families in which members are affected with both disorders, simultaneously. Both types of families may provide insight into pleiotropic genes and genes that are uniquely associated with one of both disorders: the former through simultaneously regressing gene effects on the ADHD and ASD phenotypes within families, the latter through regressing gene effects on the ADHD and ASD phenotypes within individuals.

A second (or parallel) step would be to assess candidate endophenotypes within a family-based design in which both ADHD and ASD are present in one or more family members. Endophenotypes, such as neuroimaging or neuropsychological functions, are defined as heritable vulnerability traits that form a link between genes and observable symptoms \[[@CR39]\]. The first generation of ADHD and ASD GWAS studies using the ASD or ADHD clinical phenotypes made it clear that psychiatric diagnostic phenotypes may not be optimally suited for gene discovery. Compared to phenotypes, endophenotypes may improve statistical power by (a) being more heritable than phenotypes, (b) being more easily quantifiable than dichotomous *DSM* diagnostic categories, (c) being more reliable and objective than phenotypic measures, (d) being more biologically relevant, and (e) being more useful in creating genetically homogeneous subgroups of patients. Candidate endophenotypes for ADHD + ASD would most likely show the following characteristics: (a) more impaired in ADHD + ASD probands compared to ADHD or ASD probands, (b) more impaired in parents and siblings of ADHD + ASD-probands compared to those of ADHD or ASD probands, (c) stronger correlation between siblings in ADHD + ASD families compared to those in ADHD or ASD families, (d) cross-correlating with both ADHD and ASD in family members. In extensive review on candidate ADHD + ASD endophenotypes (Rommelse et al. submitted), we concluded that executive functioning, response variability, social cognition, motor coordination, language and intelligence are the most promising candidate neuropsychological endophenotypes. Candidate structural brain endophenotypic measurements include overall brain size, corpus callosum and cerebellum size, and structural integrity of the fronto-striatal circuitry. Too little data existed on functional brain imaging measures to propose candidate endophenotypes in this domain. Body parameters that may be useful for future studies are finger length ratio, height and weight and, possibly, fatty acid abnormalities. By incorporating these candidate endophenotypes into molecular genetic studies, both statistical power as well as insight into gene-behavior pathways may be gained.

However, the endophenotype approach is not without its shortcomings. For example, it is not well established that endophenotypes are indeed more reliable and objective than clinical phenotypes \[[@CR11]\]. Furthermore, a putative endophenotype might not be less 'genetically complex' or more heritable than the phenotype itself \[[@CR11]\], thereby not automatically resulting in an increased power to detect genetic effects. For example, though useful \[[@CR78]\] and potentially more powerful than studies of clinical phenotypes, quite substantial sample sizes are still needed when endophenotypes at the level of neurocognitive performance are used for genetic studies \[[@CR11]\]. However, structural and functional neuroimaging measures do appear to be able to reduce necessary sample sizes for molecular genetic analyses considerably \[[@CR58], [@CR62]\]. Therefore, despite possible shortcomings, we would nevertheless recommend incorporating candidate endophenotypic measures in family-genetic research for ADHD + ASD.

Another recommendation is to analyze multiple endophenotypes at the same time. This could be achieved by combining related traits into a single outcome using principal component analyses or factor analyses. Hereby common underlying constructs are extracted based on covariance between measures while the number of variables is reduced. Main advantages over the use of multiple correlated endophenotypes in univariate analyses are an increased reliability and decreased risk of false positive results. A potential disadvantage of this approach may be the loss of information by removing variance that is specific to each of the endophenotypes. Alternatively, multivariate multi-level models may be used. Multivariate multi-level models flesh out the relationships between numerous intermediate phenotypes \[[@CR82]\]. Using this technique, multiple explanatory genetic variables can be simultaneously included in the model (multivariately) and regressed on variables measured at the endophenotype and phenotype level. As most cases of ADHD and ASD are probably caused by many genes of small individual effect, incorporating the relationships between multiple genes, endophenotypes and the clinical phenotypes in the model are even more important. The multivariate endophenotype approach has already proved useful in various other domains of endophenotypic research \[[@CR13], [@CR71], [@CR97]\] and will most likely prove fruitful in the search for common etiological factors for ADHD + ASD.

Last but not least, the effect of environmental variables on endophenotypic and phenotypic functioning should not be overlooked. A candidate endophenotype can be associated with a diagnosis, be heritable and be reliably assessed, but nevertheless be under (strong) influence of environmental factors. Gene--environment interactions (mainly related to early/obstetric variables) on the phenotype are increasingly reported in ADHD and ASD literature \[[@CR12], [@CR60], [@CR68], [@CR90], [@CR91]; see also elsewhere in this issue\] and may also exist for endophenotypes. Therefore, gene--environment interactions are of vital importance to take into consideration when studying a common etiological basis for both disorders.

In sum, properly designed and powered candidate gene and linkage studies are missing for ADHD + ASD. Recent GWAS for clinical ADHD and ASD phenotypes have identified a number of viable pleiotropy candidates. GWAS currently seem to be the most appropriate approaches to learn about the role of common genetic variants in the combined disorders. We propose that future studies examining shared familial etiological factors for ADHD and ASD (a) use a family-based design in which the same measurements are obtained from all family members, (b) incorporate a coherent set of candidate endophenotypic measures that are most likely shared risk factors for ADHD and ASD, (c) apply multivariate multi-level models for statistical analysis, in order to examine the relationships between the various endophenotypes and phenotypes, and (d) incorporate environmental measures into the design.
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